Share Price:

APNASPENAspen Pharmacare Hldgs16847-53 (-0.31%)

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Business Segment

Manufacturing

Aspen operates 24 manufacturing facilities spread across 15 sites. Our strategic manufacturing sites have earned international accreditation from some of the world’s most stringent global regulatory agencies. Our manufacturing capabilities encompass a wide range of product types, including steriles, oral solid doses, liquids, semi-solids, biologicals, and APIs.

Overview

Revenue by segment (%)

* Based on source of manufacture.

32%

of Group revenue

7%

of Group gross profit

Revenue
Revenue 2024
R’million
2023
R’million
%Change
Reported
CER

Finished dose form

5 262

3 970

33

24

Active pharmaceutical ingredients

5 102

5 024

2

(6)

Heparin

3 772

2 303

64

51

Total

14 136

11 297

25

16

Gross profit percentage
9,2

11,4

Manufacturing revenue grew significantly by 25%, partly aided by exchange rate tailwinds. All segments experienced growth, with the FDF segment rising by 33%, supported by the contribution from third-party contracts for sterile manufacturing. The Heparin segment surged by 64% following the strategic shift towards toll manufacture. The API segment grew by a steady 2%.
The gross profit margin declined to 9,2%, down from 11,4% in FY2023 influenced by the higher Heparin sales mix following the transition to toll manufacture and the non-recurrence of grant funding enjoyed in the prior year. In the second half of the year, the margin improved to 12,3% benefiting from the higher sterile capacity fill contribution of more than the R500 million guided.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.